1. $MRK acquired $ARQL for $2.7b in Jan ‘20 for $20/share to advance their leadership in oncology. 

$MRK collab. with $SURF in May ‘20 for a study to use SRF617 in combination with Keytruda. $SURF went from $2.8x to $7.6x when PR was announced.